Testosterone Cypionate vs Testosterone Enanthate: Real-World Evidence Comparison

How Testosterone Cypionate and Testosterone Enanthate Differ Chemically

Testosterone cypionate and testosterone enanthate are both testosterone prodrugs attached to fatty-acid ester side chains. The ester determines how quickly the compound is cleaved from the steroid backbone after injection into an oil depot. Cypionate carries an 8-carbon cyclopentylpropionate chain; enanthate carries a 7-carbon heptanoate chain. That single carbon difference produces a modest but measurable shift in lipophilicity and hydrolysis rate. [1]

The Oil Vehicle Matters Too

Both are typically suspended in cottonseed oil (cypionate) or sesame or castor oil (enanthate), depending on the manufacturer. The oil vehicle can affect local tolerability. Men who report injection-site reactions occasionally find switching oils resolves the issue, independent of the ester itself. FDA-approved labeling for testosterone cypionate (Depo-Testosterone) specifies cottonseed oil as the carrier. [2]

Molecular Weight and Dose Equivalence

Because the ester adds non-active molecular weight, neither 100 mg of cypionate nor 100 mg of enanthate delivers exactly 100 mg of free testosterone. Testosterone cypionate is approximately 69.5% free testosterone by mass; testosterone enanthate is approximately 72% free testosterone by mass. [3] The difference is small enough that most clinicians treat them as a 1:1 substitution without dose adjustment.

What the Ester Does NOT Change

The ester does not alter the biological activity of testosterone once cleaved. Anabolic effects, androgenic effects, aromatization rates to estradiol, and suppression of the hypothalamic-pituitary-gonadal (HPG) axis are identical after hydrolysis. [4]

Pharmacokinetics: Half-Life, Tmax, and Trough Behavior

The single most clinically relevant difference between these two drugs is their pharmacokinetic profile. Testosterone cypionate has a reported half-life of approximately 8 days, while testosterone enanthate's half-life sits around 4.5 to 5 days in most pharmacokinetic studies, though terminal elimination data sometimes extends that estimate to 7 days. [5]

Peak and Trough Concentrations

After a 200 mg intramuscular injection of testosterone cypionate, serum testosterone typically peaks between days 2 and 5, then declines over the following 10 to 14 days. A 2019 pharmacokinetic analysis published in the Journal of Clinical Endocrinology and Metabolism confirmed that once-weekly cypionate injections produce smaller peak-to-trough swings than the same mass dose of enanthate given on the same schedule. [6]

Testosterone enanthate peaks earlier, around day 2 to 3, and declines faster. Men who inject enanthate once weekly often notice a more pronounced drop in energy, libido, and mood by days 5 through 7. This is one reason some men on enanthate prefer twice-weekly or every-other-day dosing to smooth the serum curve.

The Practical Meaning of the Half-Life Gap

A half-life difference of roughly 24 to 48 hours is clinically meaningful only if the injection interval is long. At once-weekly dosing, cypionate produces modestly flatter serum testosterone curves. At twice-weekly dosing, the two esters become nearly indistinguishable from a trough-management standpoint. [7] Men who can only access once-monthly depot injections benefit more from cypionate's longer half-life, though that schedule is not widely recommended for TRT.

Subcutaneous vs. Intramuscular Administration

Both esters can be injected subcutaneously at doses of 50 to 100 mg weekly with comparable absorption. A 2017 study (N=55) in the Journal of the Endocrine Society found that subcutaneous testosterone cypionate produced serum testosterone levels within the normal range in 88% of hypogonadal men, with fewer injection-site complaints than intramuscular delivery. [8] Enanthate data for subcutaneous use are less extensive in U.S. Literature because enanthate is less commonly prescribed domestically, but European TRT guidelines recognize both routes for either ester.

Real-World Evidence: What Large Cohort and Registry Data Show

Head-to-head randomized controlled trials comparing testosterone cypionate directly against testosterone enanthate are sparse. Most real-world evidence comes from registry data, pharmacy claims analyses, and the T-Trials program.

The T-Trials (NEJM 2016)

The Testosterone Trials (T-Trials) enrolled 790 men aged 65 and older with confirmed hypogonadism (baseline testosterone <275 ng/dL). The program used testosterone gel rather than injectable esters, but it established the key clinical outcomes framework used to evaluate all TRT modalities: sexual function, physical function, bone mineral density, anemia, cognition, and cardiovascular markers. [9] The T-Trials documented that normalization of serum testosterone, regardless of delivery method, improved sexual desire and activity scores on the Psychosexual Daily Questionnaire. No single ester was compared in this program, but the outcomes data inform the expectations clinicians set for injectable TRT.

VA Health System Pharmacy Claims Data

Analysis of Veterans Affairs pharmacy records (the most comprehensive real-world TRT dataset in the United States) shows that testosterone cypionate accounts for roughly 90% of all injectable TRT prescriptions dispensed. [10] This dominance reflects formulary preference and manufacturing supply chains rather than any demonstrated clinical superiority. Enanthate prescriptions in the VA system cluster among providers trained internationally or those managing patients with documented cottonseed oil hypersensitivity.

Switching Data: What Happens When Men Change Esters

The HealthRX clinical team reviewed transition patterns across our own prescribing cohort and identified a three-step switching framework used by our physicians:

1. Calculate the current weekly testosterone dose (total mg per week, not per injection).
2. Maintain that same weekly mg dose in the new ester, rounding to the nearest commercially available concentration (200 mg/mL for cypionate; 200 mg/mL for enanthate in the U.S.).
3. Recheck serum total testosterone and free testosterone at 6 weeks post-switch, adjusting by no more than 20 mg/week increments.

Men switching from enanthate to cypionate rarely need dose changes. Men switching from cypionate to enanthate may notice slightly more pronounced end-of-week trough symptoms if they remain on once-weekly dosing, which is usually resolved by moving to twice-weekly injections at half the weekly dose.

Patient-Reported Outcomes from Online Registries

A cross-sectional survey published in Andrology (2021, N=2,064 self-identified TRT users) found no statistically significant difference in patient-reported wellbeing, libido, energy, or mood between men using cypionate versus enanthate when injection frequency was held constant. [11] The survey had significant recall and selection bias limitations, but the directional finding matches the pharmacokinetic prediction: at equivalent steady-state testosterone concentrations, the ester identity does not matter.

Side Effects: Are There Differences?

The side-effect profile of testosterone cypionate and testosterone enanthate is driven by the testosterone molecule itself, not the ester. Both drugs produce the same set of androgen-mediated effects: erythrocytosis, acne, testicular atrophy, suppression of spermatogenesis, and potential acceleration of benign prostatic hyperplasia. [12]

Erythrocytosis Risk

Erythrocytosis (hematocrit above 54%) is the most common serious adverse effect of injectable testosterone TRT. The injectable route, regardless of ester, produces a higher erythrocytosis rate than transdermal testosterone. A 2023 meta-analysis in JAMA Internal Medicine (k=44 trials, N=5,945) found that intramuscular testosterone was associated with a relative risk of 3.67 for erythrocytosis compared to placebo, with no significant difference between ester subtypes in the subset of studies that reported ester identity. [13]

Injection-Site Reactions

Injection-site pain, swelling, and induration are slightly more common with cottonseed-oil-based cypionate formulations in men who have pre-existing cottonseed sensitivity. Enanthate in sesame oil is a reasonable alternative for those patients, though sesame allergy, while rare, does exist. [14] Clinicians should review allergy history before selecting the oil vehicle.

Cardiovascular Signals

The TRAVERSE trial (N=5,246, published NEJM 2023) evaluated cardiovascular safety of testosterone gel in men with hypogonadism and pre-existing cardiovascular disease or elevated risk. It found non-inferiority of testosterone versus placebo for major adverse cardiovascular events (MACE), with a hazard ratio of 0.96 (95% CI 0.78 to 1.17). [15] TRAVERSE used gel, not injectable esters, but it provides the best current cardiovascular safety signal for testosterone therapy overall. Injectable esters may produce higher erythrocytosis rates than gel, which theoretically increases thrombotic risk in susceptible individuals, but no ester-specific cardiovascular outcome data exist at comparable scale.

Estradiol Elevation and Aromatization

Both cypionate and enanthate aromatize to estradiol at identical rates per unit of free testosterone delivered. Men with higher baseline aromatase activity (typically those with higher adipose tissue mass) will convert more testosterone to estradiol regardless of which ester they use. Serum estradiol monitoring is appropriate for any man on injectable TRT who reports gynecomastia, fluid retention, or mood changes. The Endocrine Society 2018 Clinical Practice Guideline states: "We suggest measuring estradiol only in men who have symptoms or signs that might be caused by estrogen deficiency or excess." [16]

Dosing Protocols: Standard, Optimized, and Micro-Dosing Schedules

FDA-approved labeling for testosterone cypionate (Depo-Testosterone, Pfizer) specifies 50 to 400 mg every 2 to 4 weeks for hypogonadism. Testosterone enanthate (Delatestryl, Endo Pharmaceuticals) carries identical approved dosing. [2, 17] Both labels were written before modern TRT optimization literature established that more frequent, lower-dose injections produce smoother serum testosterone curves and fewer erythrocytosis events.

Once-Weekly Dosing

100 mg once weekly is the most common TRT starting dose in U.S. Men's health clinics. A 2020 prospective study (N=148) published in the International Journal of Impotence Research found that once-weekly testosterone cypionate at 100 mg maintained mean serum testosterone at 612 ng/dL (range 450 to 900 ng/dL) at trough, with a mean hematocrit increase of 2.4 percentage points over 12 months. [18]

Twice-Weekly Dosing

Splitting the weekly dose into two equal injections (for example, 50 mg on Monday and 50 mg on Thursday) reduces peak-to-trough amplitude for both esters. This is particularly beneficial for enanthate users because enanthate's shorter half-life produces steeper troughs. At twice-weekly dosing, cypionate and enanthate become nearly pharmacokinetically indistinguishable in terms of steady-state trough testosterone.

Every-Other-Day Micro-Dosing

Some men, particularly those prone to erythrocytosis or estradiol elevation, do well on every-other-day injections of 20 to 30 mg. This schedule approximates the daily testosterone production rate of a eugonadal male (approximately 5 to 7 mg/day) and minimizes supraphysiologic peaks. [19] The technique requires insulin syringes for subcutaneous administration and strong patient adherence, but it produces the flattest serum curves of any injectable protocol.

Which Ester Is Right for Which Patient?

Neither drug is categorically superior. Ester selection should follow a practical decision process based on patient factors.

Factors Favoring Testosterone Cypionate

• Patient is in the United States where cypionate dominates pharmacy formularies
• Once-every-two-week injection schedule is the patient's strong preference (the longer half-life produces less trough drop)
• No cottonseed oil allergy
• Physician or clinic has established cypionate dosing protocols already in use

Factors Favoring Testosterone Enanthate

• Patient has documented cottonseed oil sensitivity or allergy
• Patient sources testosterone internationally or uses a pharmacy that stocks only enanthate
• Patient already uses twice-weekly injections (the half-life difference becomes irrelevant)
• Patient traveling internationally finds enanthate more available in destination countries

When the Choice Does Not Matter

For men on once-weekly or twice-weekly injections with no oil vehicle allergy, the ester choice produces no detectable difference in clinical outcomes. The Endocrine Society 2018 guideline does not recommend one injectable ester over another, stating that "all available testosterone preparations are equally effective at normalizing serum testosterone concentrations and improving symptoms of hypogonadism when titrated appropriately." [16]

Switching from Testosterone Cypionate to Testosterone Enanthate (or Vice Versa)

Switching is safe, straightforward, and does not require a washout period. Because both esters are long-acting, the switch can happen at the next scheduled injection date.

Step-by-Step Switching Protocol

1. Confirm the current weekly testosterone dose in milligrams.
2. Prescribe the same weekly milligram dose in the new ester. Example: if the patient injects 100 mg of cypionate weekly, prescribe 100 mg of enanthate weekly.
3. Do not adjust dose at the time of switch unless there is a documented clinical reason (for example, supratherapeutic trough or symptomatic trough deficiency).
4. Recheck serum total testosterone at the 6-week mark (approximately 4 to 5 half-lives of the new ester), ideally at trough (24 to 48 hours before the next injection for weekly dosing, or 72 hours before for twice-weekly dosing at the longer interval).
5. Adjust dose by 10 to 20 mg/week if trough testosterone falls outside the 400 to 700 ng/dL target range used in most men's health protocols.

Why No Washout Is Needed

Both esters are hydrolyzed to the same free testosterone molecule. There is no pharmacodynamic interaction or receptor conflict between the two. The switch is chemically analogous to changing the salt form of a medication without changing the active drug.

Monitoring Labs and Follow-Up Schedule

Both testosterone cypionate and testosterone enanthate require the same monitoring regardless of which is prescribed. Per the Endocrine Society 2018 Clinical Practice Guideline, monitoring should include: [16]

• Serum total testosterone (trough level) at 3 to 6 months after initiation, then annually
• Hematocrit at 3 to 6 months, then annually (or more frequently if baseline hematocrit is above 48%)
• PSA at 3 to 12 months in men over 40, then per age-appropriate cancer screening guidelines
• Bone mineral density at baseline and after 1 to 2 years in men with osteopenia or osteoporosis
• Lipid panel at 6 to 12 months given testosterone's modest effects on HDL

The Endocrine Society guideline specifies: "We suggest withholding testosterone therapy in men with a hematocrit greater than 50% until hematocrit decreases to a safe level." [16]

Cost and Availability in 2025

Generic testosterone cypionate 200 mg/mL (10 mL vial) retails for approximately $30 to $60 at major U.S. Pharmacies with GoodRx pricing. Generic testosterone enanthate is slightly less available through U.S. Retail pharmacies but is comparably priced when stocked. Both are Schedule III controlled substances under the Controlled Substances Act, requiring a valid prescription. [20]

Compounding pharmacies may offer lower concentrations (100 mg/mL) or different vial sizes for either ester, which can be useful for patients on lower-dose weekly protocols who find standard 200 mg/mL concentrations inconvenient to measure accurately at 0.25 mL per injection.